Andrew Ladwiniec

Dr. Andrew Ladwiniec


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 May 2022 in European Heart Journal
Verified
Journal Article
Open access
PDF file
TKThomas A Kite
Thomas A Kite
SKSameer A Kurmani
Sameer A Kurmani
VBVasiliki Bountziouka
Vasiliki Bountziouka
NCNicola J Cooper
Nicola J Cooper
SLSelina T Lock
Selina T Lock
ALAndrew Ladwiniec
Andrew Ladwiniec
The optimal timing of an invasive strategy (IS) in non-ST-elevation acute coronary syndrome (NSTE-ACS) is controversial. Recent randomized controlled trials (RCTs) and long-term follow-up data have yet to be included in a contemporary meta-analysis. A systematic review of RCTs that compared an early IS vs. delayed IS for NSTE-ACS was conducted by searching MEDLINE, Embase, and Cochrane Central Register of Controlled Trials. A meta-analysis was performed by pooling relative risks (RRs) using a random-effects model. The primary outcome was all-cause mortality. Secondary outcomes included myocardial infarction (MI), recurrent ischaemia, admission for heart failure (HF), repeat re-vascularization, major bleeding, stroke, and length of hospital stay. This study was registered with PROSPERO (CRD42021246131). Seventeen RCTs with outcome data from 10 209 patients were included. No significant differences in risk for all-cause mortality [RR: 0.90, 95% confidence interval (CI): 0.78–1.04], MI (RR: 0.86, 95% CI: 0.63–1.16), admission for HF (RR: 0.66, 95% CI: 0.43–1.03), repeat re-vascularization (RR: 1.04, 95% CI: 0.88–1.23), major bleeding (RR: 0.86, 95% CI: 0.68–1.09), or stroke (RR: 0.95, 95% CI: 0.59–1.54) were observed. Recurrent ischaemia (RR: 0.57, 95% CI: 0.40–0.81) and length of stay (median difference: −22 h, 95% CI: −36.7 to −7.5 h) were reduced with an early IS. In all-comers with NSTE-ACS, an early IS does not reduce all-cause mortality, MI, admission for HF, repeat re-vascularization, or increase major bleeding or stroke when compared with a delayed IS. Risk of recurrent ischaemia and length of stay are significantly reduced with an early IS. Left: Time to invasive coronary angiography in the included randomized controlled trials. The bars represent median time and interquartile ranges in the early invasive strategy group (red) and the delayed invasive strategy group (blue). The Tekin et al.17 and Liu et al.18 studies are not displayed as medians were not reported. Interquartile ranges were not reported in the OPTIMA and Zhang et al.14 trials. Right: Summary relative risks for all-cause mortality, myocardial infarction, recurrent ischaemia, admission for heart failure, repeat revascularization, major bleeding, and stroke.

1 April 2015 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Closed access
ALAndrew Ladwiniec
Andrew Ladwiniec
MCMichael S. Cunnington
Michael S. Cunnington
JRJennifer Rossington
Jennifer Rossington
AMAdam N. Mather
Adam N. Mather
AAAlbert Alahmar
Albert Alahmar
AHAngela Hoye
Angela Hoye
Background—: The presence of a concomitant chronic total coronary occlusion (CTO) and a large collateral contribution might alter the fractional flow reserve (FFR) of an interrogated vessel, rendering the FFR unreliable at predicting ischemia should the CTO vessel be revascularized and potentially affecting the decision on optimal revascularization strategy. We tested the hypothesis that donor vessel FFR would significantly change after percutaneous coronary intervention of a concomitant CTO. Methods and Results—: In consecutive patients undergoing percutaneous coronary intervention of a CTO, coronary pressure and flow velocity were measured at baseline and hyperemia in proximal and distal segments of both nontarget vessels, before and after percutaneous coronary intervention. Hemodynamics including FFR, absolute coronary flow, and the coronary flow velocity–pressure gradient relation were calculated. After successful percutaneous coronary intervention in 34 of 46 patients, FFR in the predominant donor vessel increased from 0.782 to 0.810 (difference, 0.028 [0.012 to 0.044]; P =0.001). Mean decrease in baseline donor vessel absolute flow adjusted for rate pressure product: 177.5 to 139.9 mL/min (difference −37.6 [−62.6 to −12.6]; P =0.005), mean decrease in hyperemic flow: 306.5 to 272.9 mL/min (difference, −33.5 [−58.7 to −8.3]; P =0.011). Change in predominant donor vessel FFR correlated with angiographic (%) diameter stenosis severity ( r =0.44; P =0.009) and was strongly related to stenosis severity measured by the coronary flow velocity–pressure gradient relation ( r =0.69; P <0.001). Conclusions—: Recanalization of a CTO results in a modest increase in the FFR of the predominant collateral donor vessel associated with a reduction in coronary flow. A larger increase in FFR is associated with greater coronary stenosis severity.

15 November 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
LBLiam Back
Liam Back
ALAndrew Ladwiniec
Andrew Ladwiniec
The use of saphenous vein grafts (SVGs) in the surgical management of obstructive coronary artery disease remains high despite a growing understanding of their limitations in longevity. In contemporary practice, approximately 95% of patients receive one SVG in addition to a left internal mammary artery (LIMA) graft. The precise patency rates for SVGs vary widely in the literature, with estimates of up to 61% failure rate at greater than 10 years of follow-up. SVGs are known to progressively degenerate over time and, even if they remain patent, demonstrate marked accelerated atherosclerosis. Multiple studies have demonstrated a marked acceleration of atherosclerosis in bypassed native coronary arteries compared to non-bypassed arteries, which predisposes to a high number of native chronic total occlusions (CTOs) and subsequent procedural challenges when managing graft failure. Patients with failing SVGs frequently require revascularisation to previously grafted territories, with estimates of 13% of CABG patients requiring an additional revascularisation procedure within 10 years. Redo CABG confers a significantly higher risk of in-hospital mortality and, as such, percutaneous coronary intervention (PCI) has become the favoured strategy for revascularisation in SVG failure. Percutaneous treatment of a degenerative SVG provides unique challenges secondary to a tendency for frequent superimposed thrombi on critical graft stenoses, friable lesions with marked potential for distal embolization and subsequent no-reflow phenomena, and high rates of peri-procedural myocardial infarction (MI). Furthermore, the rates of restenosis within SVG stents are disproportionately higher than native vessel PCI despite the advances in drug-eluting stent (DES) technology. The alternative to SVG PCI in failed grafts is PCI to the native vessel, ‘replacing’ the grafts and restoring patency within the previously grafted coronary artery, with or without occluding the donor graft. This strategy has additional challenges to de novo coronary artery PCI, however, due to the high burden of complex atherosclerotic lesion morphology, extensive coronary calcification, and the high incidence of CTO. Large patient cohort studies have reported worse short- and long-term outcomes with SVG PCI compared to native vessel PCI. The PROCTOR trial is a large and randomised control trial aimed at assessing the superiority of native vessel PCI versus vein graft PCI in patients with prior CABG awaiting results. This review article will explore the complexities of SVG failure and assess the contemporary evidence in guiding optimum percutaneous interventional strategy.

15 June 2026 in Circulation
Verified
Journal Article
Open access
CSChristian Spaulding
Christian Spaulding
FKFlorian Krackhardt
Florian Krackhardt
KBKris Bogaerts
Kris Bogaerts
EAEltigani Abdelaal
Eltigani Abdelaal
FAFernando Alfonso
Fernando Alfonso
SPSonia Petronio
Sonia Petronio
BACKGROUND: Implantation of drug eluting stents (DESs) is currently the default approach for percutaneous coronary interventions, but long-term adverse events still exist. An approach with minimal stenting deserves to be assessed in a randomized trial. We studied a novel sirolimus-eluting balloon (SEB) that elutes sirolimus over a 90-day period using a biodegradable polymer microreservoir technology. METHODS: In a multicenter, open-label, randomized trial, we compared an SEB-based strategy with provisional DES with one of systematic DES for de novo lesions in coronary arteries between 2 and 5 mm in diameter. Subjects were randomized 1:1 before percutaneous coronary intervention. The primary end point was target vessel failure, a composite of cardiac death, target vessel–related myocardial infarction, and clinically driven target vessel revascularization. It was tested for noninferiority at 1 year with the use of an absolute margin equal to 50% of the combined event rate at a significance level of 0.025. The primary analysis population included all randomized subjects with completed or attempted percutaneous revascularization, analyzed according to the intention-to-treat principle. A sensitivity analysis was performed on the per-protocol population. RESULTS: Between August 27, 2021, and July 29, 2024, 3323 participants were randomized and treated in 62 sites. Among 1661 participants in the SEB strategy group, bailout stenting was performed in 343 (20.7%). Target vessel failure occurred over 365 days in 88 (5.3%) and 73 (4.4%) participants in the SEB and the systematic DES strategy groups, respectively (risk difference, 0.91% [95% CI –0.55% to 2.38%]; 1-sided P =0.02 for noninferiority with a 2.44% noninferiority margin). Clinically driven target vessel revascularization occurred more frequently in the SEB strategy group (3.3% versus 2.1%; risk difference, 1.22% [95% CI, 0.11%–2.33%). Safety events, including lesion thrombosis, were low and similar in both groups. Although the results of the per-protocol population (3194 participants, 96%) did not confirm noninferiority (upper boundary of the 95% CI, 2.63; P =0.04), they were similar to the intention-to-treat results in both magnitude and direction. CONCLUSIONS: At 1 year, in the primary intention-to-treat analysis population, a strategy of percutaneous coronary intervention with SEB and provisional DES was noninferior to the systematic use of DES for the primary end point of target vessel failure. The per-protocol population sensitivity analysis did not confirm noninferiority. Clinically driven target vessel revascularization occurred more frequently in the SEB strategy group. At 5 years, target vessel failure will be tested again for noninferiority and for superiority if noninferiority is achieved. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04859985.

25 November 2025 in European Heart Journal
Verified
Journal Article
Open access
HMHasan Mohiaddin
Hasan Mohiaddin
SSShirley Sze
Shirley Sze
ADAbdulla A Damluji
Abdulla A Damluji
ALAndrew Ladwiniec
Andrew Ladwiniec
GMGerry P McCann
Gerry P McCann
MRMuhammad Rashid
Muhammad Rashid
Background and Aims: Frailty is increasingly recognized as an important determinant of adverse outcomes in older adults with acute myocardial infarction (AMI), but its impact in younger patients remains underexplored. The aims of this study were to evaluate the association of frailty with adverse outcomes in AMI patients, stratified by age. Methods: This population-based epidemiological study utilized linked national administrative data from England and Wales. Patients were stratified into three age groups: <55 years, 55–74 years, and ≥75 years. Frailty was assessed using the Secondary Care Administrative Records Frailty index with patients categorized into fit, mild, moderate, and severe groups. All-cause mortality at 1 year was the primary outcome. Secondary outcomes were cardiovascular and bleeding-related events. Results: A total of 931 133 patients were included of which 13% of patients were severely frail. In patients with severe frailty, adjusted hazard ratios for all-cause mortality were 6.69 [95% confidence interval (CI) 5.76–7.76] for young patients, 4.33 (95% CI 4.11–4.57) for middle-aged patients, and 2.31 (95% CI 2.23–2.39) for older patients. The interaction between age and frailty revealed that younger patients with severe frailty had a 3.51-fold (95% CI 3.11–3.96) higher risk of all-cause mortality compared with older patients with severe frailty (P < .001). Conclusions: Frailty is independently associated with poor outcomes after AMI, with the strongest impact observed in younger patients, highlighting the need for frailty assessment across all age groups.

12 January 2016 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
ALAndrew Ladwiniec
Andrew Ladwiniec
MCMichael S. Cunnington
Michael S. Cunnington
JRJennifer Rossington
Jennifer Rossington
STSimon Thackray
Simon Thackray
FAFarquad Alamgir
Farquad Alamgir
AHAngela Hoye
Angela Hoye